
    
      Gastric cancer patients who will receive neoadjuvant chemotherapy would be included in this
      study. They would receive combined intravenous and intra-arterial intensified SEEOX
      neoadjuvant chemotherapy or SOX regimen at random. The efficacy and toxicity of these two
      regimens would be compared.
    
  